Researchers at the Icahn School of Medicine at Mount Sinai, reporting in Nature Communications, found that a protein called TIMP2 plays a role in keeping the brain's immune cells working well as animals age. When the team removed TIMP2 from mice, the brain's immune cells, known as microglia, took on traits linked to aging and neurodegenerative disease. When they restored TIMP2 in the bloodstream of older mice, those cells got better at clearing cellular debris and showed fewer molecular signs of inflammation and other potentially harmful changes.
Aging is the greatest known risk factor for Alzheimer's disease and other neurodegenerative disorders, yet scientists still lack a full picture of why the aging brain becomes more vulnerable. Microglia are central to that question. They remove cellular waste, help maintain the connections between neurons, and respond to injury. As the brain ages, these cells can lose those abilities and shift into states that promote inflammation.
To probe TIMP2's role, the team compared several groups of mice, some lacking the protein throughout the body and others missing it only in microglia or only in neurons. They combined single-nucleus RNA sequencing, imaging, functional tests, and in vivo microdialysis, which measures substances in the fluid around cells in living brain tissue. Microglia lacking TIMP2 showed changed activation markers, reduced debris clearance, and signatures linked to cellular senescence. The microdialysis work also detected higher levels of inflammation- and stress-associated proteins in the surrounding environment.
The researchers then injected TIMP2 into older mice so it could circulate through the body. Microglia became more effective at clearing debris and showed reduced markers associated with inflammatory states. Dr. Joseph M. Castellano, the corresponding author, said the protein may help restore microglial functions that become compromised with age, and noted that earlier work from his lab had linked TIMP2 to synaptic plasticity, the brain's ability to strengthen or weaken connections between neurons.
The authors are clear about the limits of the work. These findings come from mice, and it is not yet known whether TIMP2 would have similar effects in people or whether targeting it could become a treatment. Further studies are needed to determine whether TIMP2 itself or the pathways it controls could be aimed at the harmful changes linked to brain aging.